Drug Trial News

RSS

Monoclonal antibody decreases asthma attacks by 27% in children and adolescents of color

A monoclonal antibody, mepolizumab, decreased asthma attacks by 27% in Black and Hispanic children and adolescents who have a form of severe asthma, are prone to asthma attacks and live in low-income urban neighborhoods, a National Institutes of Health clinical trial has found.

10 Aug 2022

Researchers identify novel molecular pathway that suppresses the spread of glioblastoma

UT Southwestern researchers have identified a molecular pathway responsible for the spread of glioblastoma to surrounding tissue in the brain, as well as an existing drug that curbed tumor growth in animal models.

10 Aug 2022

Next-generation monoclonal antibody prevents malaria

Researchers investigate the pharmacokinetics and safety of L9LS, a monoclonal antibody to prevent malaria.

9 Aug 2022

Should pregnant women be included clinical trials?

The current study reports some of the scientific, ethical, and legal considerations that will support the inclusion of pregnant women in future research.

8 Aug 2022

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Researchers from Japan today reported that the first phase II study to evaluate the efficacy and safety of durvalumab and concurrent curative radiation therapy for PD-L1-positive unresectable locally advanced non-small cell lung cancer without chemotherapy met its primary endpoint with tolerable adverse reactions.

8 Aug 2022

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Following concurrent chemoradiation for unresectable stage III non-small cell lung cancer, both nivolumab alone and nivolumab and ipilimumab combined demonstrated improved 18- month progression-free survival compared with historical controls despite a shortened interval (6 months) of treatment.

8 Aug 2022

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

In the initial NADIM trial, neoadjuvant chemoimmunotherapy was shown to be highly effective in patients with resectable stage IIIA non-small cell lung cancer.

8 Aug 2022

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy (cCRT) or sequential chemoradiotherapy (sCRT), according to findings presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna.

8 Aug 2022

Monoclonal antibody protects U.S. adults from malaria, Phase 1 clinical trial shows

One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine.

4 Aug 2022

TransCode and MD Anderson scientists collaborate to validate therapeutic and diagnostic candidates

The University of Texas MD Anderson Cancer Center and TransCode Therapeutics, Inc. today announced a strategic alliance to advance TransCode's pipeline of RNA-targeted oncology therapeutic and diagnostic candidates.

2 Aug 2022

New trial offers double the traditional course of antibiotics for patients with life threatening infections

Hospital patients who develop infections where 10% of sufferers die will be offered double the traditional course of antibiotics in a new trial.

1 Aug 2022

Is cannabidiol effective against COVID-19?

A new study discusses the utility of CBD in treating the inflammatory symptoms of COVID-19

31 Jul 2022

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

With this approval, RINVOQ® is the first and only Janus Kinase inhibitor approved to treat patients across the spectrum of axial spondyloarthritis (nr-axSpA and ankylosing spondylitis) in the EU.

From AbbVie 29 Jul 2022

Oncology trial data not available for independent scrutiny, study finds

Despite a commitment from the pharmaceutical industry in 2014 to improve data transparency, more than half of the clinical trials that led to the United States Food and Drug Administration approving anticancer medicines over the past 10 years are not available for independent scrutiny, a multi-national study led by Flinders University has found.

28 Jul 2022

FDA clears IND application for MD Anderson-sponsored Phase I clinical study of OBX-115 therapy

The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for an MD Anderson-sponsored Phase I clinical study of OBX-115, Obsidian's lead engineered tumor infiltrating lymphocyte (TIL) therapy candidate.

21 Jul 2022

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

AbbVie today announced it has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least four migraine days per month.

From AbbVie 21 Jul 2022

Nanotherapeutic compound may help treat inflammation, brain injury in patients with severe COVID-19

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chances of death, according to a new study from UTHealth Houston and other institutions.

20 Jul 2022

The potential of circular RNA COVID-19 vaccines

A new MedComm study describes the potential use of circular ribonucleic acid COVID-19 vaccines.

17 Jul 2022

Lumasiran shows efficacy and acceptable safety in patients with PH1 and advanced kidney disease

In patients with PH1 and advanced kidney disease, including patients on hemodialysis, use of Lumasiran shows substantial reductions in plasma oxalate levels with acceptable safety.

14 Jul 2022

Phase I clinical trial of new blocking antibody therapy shows promising results for the treatment of advanced medulloblastoma

Effective and safe treatments are needed for medulloblastoma-;the most common type of cancerous brain tumor in children-;especially for patients whose cancer has spread to the spinal cord.

14 Jul 2022

Previous
1
...
30
31
32
33
34
35
36
...
1143
Next

Drug Trial News

Monoclonal antibody decreases asthma attacks by 27% in children and adolescents of color

Researchers identify novel molecular pathway that suppresses the spread of glioblastoma

Next-generation monoclonal antibody prevents malaria

Should pregnant women be included clinical trials?

First Phase II study of immunotherapy combined with curative radiotherapy for unresectable locally advanced NSCLC

Consolidation PD-(L)1 inhibition following concurrent chemoradiation for unresectable stage III NSCLC improves survival

Neoadjuvant chemoimmunotherapy highly effective in patients with resectable stage IIIA NSCLC

Trial evaluates sugemalimab as a consolidation treatment in patients with unresectable stage III NSCLC

Monoclonal antibody protects U.S. adults from malaria, Phase 1 clinical trial shows

TransCode and MD Anderson scientists collaborate to validate therapeutic and diagnostic candidates

New trial offers double the traditional course of antibiotics for patients with life threatening infections

Is cannabidiol effective against COVID-19?

RINVOQ® (upadacitinib) Approved by European Commission as an Oral Treatment for Adults with Active Non-Radiographic Axial Spondyloarthritis

Oncology trial data not available for independent scrutiny, study finds

FDA clears IND application for MD Anderson-sponsored Phase I clinical study of OBX-115 therapy

AbbVie Submits Marketing Authorization Application to EMA for Atogepant for the Preventive Treatment of Migraine

Nanotherapeutic compound may help treat inflammation, brain injury in patients with severe COVID-19

The potential of circular RNA COVID-19 vaccines

Lumasiran shows efficacy and acceptable safety in patients with PH1 and advanced kidney disease

Phase I clinical trial of new blocking antibody therapy shows promising results for the treatment of advanced medulloblastoma

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News